Impact of local tissue inflammation on intramyocardial conduction pathways post percutaneous valve : evaluation by positron emission tomography on exploratory cohort

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-514587-44-00

Acronym

29BRC21.0255

Enrollment

100

Registered

2024-06-17

Start date

Unknown

Completion date

Unknown

Last updated

2025-11-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aortic stenosis

Brief summary

Intra-hospital "occurrence of a conductive disorder", a composite criterion comprising: 1) complete AVB, 2) high-grade AVB, 3) LBB, 4) RBB, 5) AVB1; assessed by electrocardiograms (ECG post percutaneous valve implantation) performed during the initial hospitalization

Detailed description

Post-TAVI pacemaker implantation, Post-TAVI pacemaker dependence at 1 month, 6 months, "Occurrence of a conductive disorder" within 6 months of discharge from TAVI hospitalization

Interventions

DRUGFLUDESOXYGLUCOSE (18F)-CURIUM 185 MBq/mL

DRUGsolution injectable

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Intra-hospital "occurrence of a conductive disorder", a composite criterion comprising: 1) complete AVB, 2) high-grade AVB, 3) LBB, 4) RBB, 5) AVB1; assessed by electrocardiograms (ECG post percutaneous valve implantation) performed during the initial hospitalization	—

Secondary

Measure	Time frame
Post-TAVI pacemaker implantation, Post-TAVI pacemaker dependence at 1 month, 6 months, "Occurrence of a conductive disorder" within 6 months of discharge from TAVI hospitalization	—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026